Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 625 of 1294 entries
View as:

Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis

Phase: N/A Priority: Normal
NCT ID: NCT00431132 Org: User:
Start: 01/31/07 End: 11/30/08 Due: 11/30/09

Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis

Phase: N/A Priority: Normal
NCT ID: NCT01486979 Org: User:
Start: 01/31/07 End: 05/31/07 Due: 05/31/08

A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01849289 Org: User:
Start: 06/02/13 End: 05/15/14 Due: 05/15/15

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00106366 Org: User:
Start: 03/31/05 End: 12/31/05 Due: 12/31/06

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT03018028 Org: User:
Start: 01/10/17 End: 08/15/18 Due: 08/15/19

Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00771680 Org: User:
Start: 10/31/08 End: 07/31/10 Due: 07/31/11

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

Phase: N/A Priority: Normal
NCT ID: NCT00634842 Org: User:
Start: 02/29/08 End: 10/31/08 Due: 10/31/09

Safety and Tolerability of Liraglutide in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01507272 Org: User:
Start: 03/31/99 End: 12/31/99 Due: 12/31/00

Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01045447 Org: User:
Start: 01/31/10 End: 10/31/10 Due: 10/31/11

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Phase: N/A Priority: Normal
NCT ID: NCT04575181 Org: User:
Start: 10/21/20 End: 12/24/21 Due: 12/24/22

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT02220296 Org: User:
Start: 08/20/14 End: 03/31/15 Due: 03/31/16

Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents

Phase: N/A Priority: Normal
NCT ID: NCT00715780 Org: User:
Start: 06/30/08 End: 07/31/09 Due: 07/31/10

Efficacy Study of IL-21 to Treat Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00336986 Org: User:
Start: 09/30/04 End: 10/31/07 Due: 10/31/08

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02500706 Org: User:
Start: 05/04/16 End: 08/16/17 Due: 08/16/18

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01731600 Org: User:
Start: 02/20/13 End: 09/28/18 Due: 09/28/19

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02479022 Org: User:
Start: 06/30/15 End: 12/31/15 Due: 12/31/16

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02003677 Org: User:
Start: 11/29/13 End: 08/14/14 Due: 08/14/15

Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT00665093 Org: User:
Start: 05/31/07 End: 01/31/08 Due: 01/31/09

Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India

Phase: N/A Priority: Normal
NCT ID: NCT03070704 Org: User:
Start: 08/16/17 End: 08/16/19 Due: 08/16/20

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Phase: N/A Priority: Normal
NCT ID: NCT03021187 Org: User:
Start: 02/02/17 End: 08/22/18 Due: 08/22/19

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01480180 Org: User:
Start: 01/30/12 End: 12/10/18 Due: 12/10/19

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT02035384 Org: User:
Start: 06/05/14 End: 01/15/20 Due: 01/15/21

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02094521 Org: User:
Start: 03/31/14 End: 07/31/14 Due: 07/31/15

Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01865305 Org: User:
Start: 09/30/06 End: 02/28/07 Due: 02/28/08

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Phase: N/A Priority: Normal
NCT ID: NCT00184730 Org: User:
Start: 11/30/04 End: 09/30/06 Due: 09/30/07